How is Novo Nordisk staking up against Eli Lilly?

Novo Nordisk, Europe’s largest listed company, has had a respectable 2024 performance on the stock market (+14.5% to date), but is a long way from that of its rival Eli Lilly (+54%). Both laboratories were the first to launch treatments for obesity, a class of drugs that currently dominates all othe…
© MarketScreener.com 2024